Avalyn Pharma Inc. (AVLN)
NASDAQ · Manufacturing · Pharmaceutical preparations
AVLN price, last 12 months
Key stats
- Previous close
- $28.55
- Open
- $28.52
- Day range
- $27.00 – $28.53
- 52-week range
- $24.15 – $40.17
- Volume
- 223.1K
- Avg volume (20 days)
- 254.2K
- Market cap
- $1.2B
Performance
Technicals and fundamentals
About Avalyn Pharma Inc.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.2B